Admescope customers can now take advantage of the benefits offered by Plexpress’ novel TRAC technology. These include higher sample throughput, increased assay speed and reduced technical variation when compared to similar gene expression analyses undertaken using qPCR or microarrays. In the first instance, Admescope will offer Plexpress’ well-validated multiplex assays targeting the Cytochrome P450 (CYP) family, which can be used as an insightful indicator of potential drug toxicity and efficacy. The new service is particularly well suited to meeting recent draft recommendations from the FDA, which suggest that CYP mRNA analysis might be more informative for drug metabolism studies than measuring CYP activity (1).
1. FDA Guidance for Industry Report (Feb 2012): Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations